Literature DB >> 23530641

Prediction of posttreament significant body weight loss and its correlation with disease-free survival in patients with oral squamous cell carcinomas.

Young-Wook Cho1, Jong-Lyel Roh, Jae Hoon Jung, Sung-Bae Kim, Sang-wook Lee, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim, Sang Yoon Kim.   

Abstract

Significant loss of body weight (SLW) by patients treated for squamous cell carcinomas of the oral cavity and oropharynx (OSCC) may affect treatment completion and results. We assessed factors predicting SLW and its correlation with disease-free survival (DFS) in these patients. We evaluated 226 consecutive patients with previously untreated, operable OSCC whose body weight was recorded before, during, and for up to 1 year after treatment. SLW was defined as ≥10% reduction in pretreatment body weight. Clinicopathologic parameters were compared in patients with and without SLW. Of the 226 patients, 94 (41.6%) experienced SLW and 132 (58.4%) did not. Univariate analyses showed that factors significantly associated with SLW included T3-4, N+, stage III-IV, and oropharyngeal tumors, nonsurgical (radiotherapy or chemotherapy) vs. surgical treatment, posttreatment recurrence, histologic differentiation, involved resection margin, and number of metastatic lymph nodes (pLNs) ≥ 3 (P < 0.05). Multivariate analyses showed that radiotherapy, recurrence, and number of pLNs were significant independent predictors of SLW (P < 0.005). DFS rate was significantly higher in patients without than with SLW (P < 0.01). OSCC patients with multiple pLNs, those undergoing radiotherapy, and those with posttreatment recurrences may require close nutritional monitoring and support.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23530641     DOI: 10.1080/01635581.2013.767365

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  7 in total

1.  Impact of weight loss on survival after chemoradiation for locally advanced head and neck cancer: secondary results of a randomized phase III trial (SAKK 10/94).

Authors:  Pirus Ghadjar; Stefanie Hayoz; Frank Zimmermann; Stephan Bodis; David Kaul; Harun Badakhshi; Jacques Bernier; Gabriela Studer; Ludwig Plasswilm; Volker Budach; Daniel M Aebersold
Journal:  Radiat Oncol       Date:  2015-01-17       Impact factor: 3.481

2.  Critical weight loss predicts poor prognosis in nasopharyngeal carcinoma.

Authors:  Qi Zeng; Lu-Jun Shen; Xiang Guo; Xin-Ming Guo; Chao-Nan Qian; Pei-Hong Wu
Journal:  BMC Cancer       Date:  2016-02-29       Impact factor: 4.430

3.  Impact of adaptive intensity-modulated radiotherapy on the neutrophil-to-lymphocyte ratio in patients with nasopharyngeal carcinoma.

Authors:  Ning Han; Xintong Lyu; Guang Li; Qiao Qiao
Journal:  Radiat Oncol       Date:  2019-08-22       Impact factor: 3.481

4.  Impact of Platelets to Lymphocytes Ratio and Lymphocytes during Radical Concurrent Radiotherapy and Chemotherapy on Patients with Nonmetastatic Esophageal Squamous Cell Carcinoma.

Authors:  Yaotian Zhang; Ning Han; Xue Zeng; Chaonan Sun; Shichen Sun; Xinchi Ma; Yanyu Zhang; Zhuang Liu; Zilan Qin; Hong Guo; Yubing Li; Na Zhang
Journal:  J Oncol       Date:  2022-04-29       Impact factor: 4.375

5.  Critical weight loss is a major prognostic indicator for disease-specific survival in patients with head and neck cancer receiving radiotherapy.

Authors:  J A E Langius; S Bakker; D H F Rietveld; H M Kruizenga; J A Langendijk; P J M Weijs; C R Leemans
Journal:  Br J Cancer       Date:  2013-08-08       Impact factor: 7.640

6.  Prognostic values of hematological biomarkers in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.

Authors:  Lulu Ye; Ronald Wihal Oei; Fangfang Kong; Tingting Xu; Chunying Shen; Xiaoshen Wang; Xiayun He; Lin Kong; Chaosu Hu; Hongmei Ying
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-03-27       Impact factor: 2.503

7.  Matched pair analysis to evaluate weight loss during radiation therapy for head and neck cancer as a prognostic factor for survival.

Authors:  Hye Ri Han; Gregory M Hermann; Sung Jun Ma; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni A Kuriakose; Michael R Markiewicz; Jon M Chan; Mary E Platek; Andrew D Ray; Fangyi Gu; Wesley L Hicks; Anurag K Singh
Journal:  Ann Transl Med       Date:  2021-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.